Key Developments: Acura Pharmaceuticals Inc (ACUR.OQ)

ACUR.OQ on NASDAQ Stock Exchange Capital Market

1.98USD
1 Aug 2013
Price Change (% chg)

$-0.06 (-2.94%)
Prev Close
$2.04
Open
$1.99
Day's High
$2.01
Day's Low
$1.90
Volume
57,968
Avg. Vol
92,365
52-wk High
$4.49
52-wk Low
$1.06

Search Stocks

Latest Key Developments (Source: Significant Developments)

Acura Pharmaceuticals Inc Submits Investigational New Drug Application
Thursday, 20 Dec 2012 08:00am EST 

Acura Pharmaceuticals Inc announced that Investigational New Drug application (IND) has been filed with the U.S. Food and Drug Administration (FDA) to allow clinical testing of Acura's hydrocodone bitartrate with acetaminophen formulated with Aversion Technology. Clinical testing can commence under the IND 30 days following the IND filing unless questions are raised by the FDA. An open IND is required for Acura to initiate intranasal abuse liability testing in recreational drug users of the crushed drug product.  Full Article

Pfizer Inc To Return Rights To Three Acura Pharmaceuticals, Inc.'s Products-Reuters
Friday, 27 Jul 2012 06:02pm EDT 

Reuters reported that Pfizer Inc will return three products it was developing using Acura Pharmaceuticals Inc's abuse resistant technology, Acura said on July 27, 2012. The license termination, which concerns three clinical stage products using Acura's Aversion technology, will be effective a year from Thursday, when Pfizer notified Acura. The Pfizer will retain rights to Oxecta and return all assets and regulatory and clinical responsibility related to the three drugs, MacKay Jimeson, a spokesman for Pfizer, told Reuters via email. Acura had received an aggregate of $78.5 million in payments from Pfizer as of March 31, under their 2007 license agreement. It was eligible to receive tiered royalties of 5% to 25% on combined annual net sales of all products marketed under the agreement.  Full Article

Kahn Swick & Foti, LLC Announces Class Action Settlement On Behalf Of Purchasers Of Publicly-Traded Securities Of Acura Pharmaceuticals Inc.
Monday, 28 Nov 2011 08:00am EST 

Kahn Swick & Foti, LLC announced that the United States District Court Northern District of Illinois Eastern Division approved the following announcement of a proposed class action settlement that would benefit purchasers of publicly-traded securities of Acura Pharmaceuticals, Inc. Pursuant to an Order of the United States District Court for the Northern District of Illinois , Eastern Division, that a hearing will be held on February 16, 2012 at 9:15 a.m. , before the Honorable Virginia M. Kendall at the Everett McKinley Dirksen United States Courthouse, 219 South Dearborn Street, Courtroom 2319, Chicago, IL 60604, for the purpose of determining; whether the proposed Class(1) can be certified for settlement purposes only, pursuant to Federal Rule of Civil Procedure 23; whether the proposed Settlement for the sum of $1,500,000 in cash should be approved by the Court as fair, reasonable and adequate; whether, after the hearing, this Action should be dismissed with prejudice pursuant to the terms and conditions set forth in the Stipulation and Settlement dated as of October 31, 2011 ; whether the Plan of Allocation is fair, reasonable and adequate and should be approved; and whether the application of Lead Counsel for the payment of attorneys' fees and reimbursement of expenses incurred in this Action should be approved.  Full Article

Acura Pharmaceuticals Inc Secures U.S. Patent For Abuse Deterrent Drug Formulations
Tuesday, 27 Sep 2011 04:15pm EDT 

Acura Pharmaceuticals, Inc. announced that the Company has been issued U.S. Patent No. 7,981,439 by the United States Patent and Trademark Office. Claims in the patent, titled Methods and compositions for deterring abuse of drugs susceptible to abuse and dosage forms thereof, cover Acura's AVERSION polymer matrix technology when utilized with any water soluble drug of abuse. The opioid, stimulant and benzodiazepine products being developed by Acura are covered by this newly issued patent.  Full Article

Search Stocks